Detection and Quantification of Atrial Fibrillation in High-risk Patients Using a Smartwatch Wearable (Apple Watch)
NCT ID: NCT05686330
Last Updated: 2025-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
436 participants
INTERVENTIONAL
2022-11-16
2025-07-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Study of Apple Watch Electrocardiographic Diagnostic Performance Enhanced by an Artificial Intelligence Algorithm
NCT04792905
Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation
NCT04809922
Heart Watch Study: a Pragmatic Randomized Controlled Trial
NCT04468321
Observational Clinical Investigation of EKG Diagnostic Performance of the Apple Watch Augmented With an AI Algorithm
NCT05045456
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial
NCT06671171
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are randomized to either smartwatch-based monitoring or standard care. Participants in the intervention group receive an Apple Watch paired with a smartphone app and are instructed to wear the device for at least 12 hours per day. Continuous rhythm monitoring is performed using PPG, with ECGs recorded upon symptom onset or irregular rhythm detection. ECG data are transmitted via the app to a secure platform and reviewed within 24 hours by an independent eHealth team supervised by a cardiologist. Patients and their treating physicians are notified upon new AF diagnoses.
To evaluate the primary endpoint, a total of 218 patients per arm were required according to the sample size calculation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional group (Apple watch)
These participants will wear a smartwatch (Apple Watch) for 6 months during 12 hours a day. The smartwatch will alarm the participant if an irregular heart rhythm is detected. When a participant experiences any symptoms or receives an irregular heartbeat notification, they can record an ECG with the smartwatch. The ECG will automatically be sent to the Telecure team for evaluation.
Apple Watch
Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
Control group
Patients in the control group received standard care, which could include conventional rhythm monitoring methods such as Holter monitoring, in-hospital telemetry, or the use of handheld mobile ECG devices, at the discretion of the treating cardiologist. At the end of the study period the investigator will either call the participant to check for these outcome measures.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apple Watch
Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chadsvasc score ≥2 for men and ≥ for women at the time of eligibility screening
* Written informed consent as documented by signature from the participant
* Possession of iPhone (6S or later)
Exclusion Criteria
* Currently on anticoagulation therapy
* Cardiac implanted electronic device (pacemaker, ICD)
* Smartwatch cannot be worn due to comprehensible reasons (allergic reactions, wounds, amputations, other)
* Significant mental or cognitive impairment
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Arthur A. M. Wilde
Prof. Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Center of the Netherlands
Amsterdam, North Holland, Netherlands
Spaarne Gasthuis
Haarlem, North Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021_209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.